Vertaling van "may " (Frans → Nederlands) :

TERMINOLOGIE

Anomalie (granulation) (granulocyte) ou syndrome de:Alder | May-Hegglin | Pelger-Huët | Hypersegmentation | Hyposegmentation | leucocytaire, héréditaire | Leucomélanopathie héréditaire
anomalie (granulatie)(granulocyt) of syndroom van | Alder | anomalie (granulatie)(granulocyt) of syndroom van | May-Hegglin | anomalie (granulatie)(granulocyt) of syndroom van | Pelger-Huët | hereditaire | leukocytaire | hypersegmentatie | hereditaire | leukocytaire | hyposegmentatie | hereditaire | leukomelanopathie

IN-CONTEXT TRANSLATIONS

Steroids may be masking undiagnosed cases of Churg-Strauss syndrome.
Steroids may be masking undiagnosed cases of Churg-Strauss syndrome .

Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.
This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.

The tender offer materials may be obtained at no charge by directing a request by mail to Morrow & Co., LLC or by calling toll-free at (800) 607-0088 or (203) 658-9400, and may also be obtained at no charge at www.pfizer.com and the website maintained by the SEC at www.sec.gov. Additionally, any questions related to the tender offer may be directed to Morrow & Co., LLC at the mailing address or telephone numbers provided above.
The tender offer materials may be obtained at no charge by directing a request by mail to Morrow & Co., LLC or by calling toll-free at (800) 607-0088 or (203) 658-9400, and may also be obtained at no charge at www.pfizer.com and the website maintained by the SEC at www.sec.gov.

This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.

Pfizer Invites Public To View And Listen To Webcast Of May 1 Conference Call With Analysts
Pfizer Invites Public To Listen To Webcast Of April 26 Annual Meeting Of Shareholders

“AD caregivers are typically the first to notice when their loved one’s symptoms are becoming worse and whether the disease may be progressing to the next stage, which is why caregivers are essential partners in disease management discussions,” said Barry W. Rovner, M.D., director of the Division of Geriatric Psychiatry and professor in the departments of Neurology and Psychiatry at Thomas Jefferson University , Philadelphia .
“AD caregivers are typically the first to notice when their loved one’s symptoms are becoming worse and whether the disease may be progressing to the next stage, which is why caregivers are essential partners in disease management discussions,” said Barry W. Rovner, M.D., director of the Division of Geriatric Psychiatry and professor in the departments of Neurology and Psychiatry at Thomas Jefferson University, Philadelphia.

R. Pumphrey et S. Davis: Under-reporting of antibiotic anaphylaxis may put patients at risk.
R. Pumphrey en S. Davis: Under-reporting of antibiotic anaphylaxis may put patients at risk.

Suite à ces nouvelles données, l’EMA a publié un avertissement (via www.ema.europa.eu (mots-clé: drospirenone; choisir : " PhVWP Monthly Report May 2011" ) et les RCP des spécialités à base de drospirénone (Yasmin®, Yasminelle® et Yaz®) ont été adaptés dans ce sens.
De odds-verhouding (schatting van het relatieve risico), gecorrigeerd voor leeftijd, bedroeg in de ene studie 2,7 (95 % betrouwbaarheidsinterval van 1,5 tot 4,7), in de andere studie 2,8 (95 % betrouwbaarheidsinterval van 2,1 tot 3,8). Naar aanleiding van deze nieuwe gegevens publiceerde het EMA een waarschuwing (via www.ema.europa.eu (zoekterm: drospirenone; kies: " PhVWP Monthly Report May 2011" ) en de SKP’s van de specialiteiten op basis van drospirenon (Yasmin®, Yasminelle® en Yaz®) werden in die zin aangepast.

Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties related to the acquisition of King by Pfizer that could cause results to differ from expectations include: uncertainties as to the timing of the merger; the possibility that a governmental entity may prohibit or delay the consummation of the merger; and the risk of shareholder litigation, including the disposition of currently pending litigation, in connection with the merger.
Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties.